New Study Shows Promise for Early Diagnosis of Ovarian Cancer with Urine Test
A recent study presented at the 68th Biophysical Society Annual Meeting in Philadelphia, Pennsylvania, has shown promise for the early diagnosis of ovarian cancer using a urine test. The study, conducted at Commonwealth University, utilized nanopore technology to detect peptides in the urine of women with ovarian cancer.
Previous research has identified thousands of small molecules, called peptides, in the urine of women with ovarian cancer. Detecting these peptides in a low-cost and efficient manner has been a challenge for experts in the field. The team at Commonwealth University sought to address this issue by utilizing nanopore technology, which has the potential to simultaneously detect multiple peptides.
The method developed by the research team is capable of identifying and analyzing multiple peptides simultaneously. In their study, the experts identified and analyzed 13 peptides, including those derived from LRG-1, a biomarker found in the urine of ovarian cancer patients.
Clinical data has shown that early detection of ovarian cancer can lead to a 50-75% improvement in 5-year survival rates. The researchers believe that the system developed in this study points towards the possibility of developing a simple test, which, combined with other information such as blood tests, transvaginal ultrasound, and family history, could improve the early diagnosis of ovarian cancer in the future.
The potential for a simple and non-invasive urine test to aid in the early detection of ovarian cancer is a significant development in the field. As further research is conducted, this method could prove to be a valuable tool in improving outcomes for women at risk of ovarian cancer.
For the full article, please visit ANSA.it.